Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose combination of bempedoic acid, ezetimibe, and atorvastatin bioequivalence study
NCT07235189Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atorvastatin + ezetimibe + bempedoic acid in hypercholesterolemia (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Area Under the Curve at 72 hours and Maximum Observed Concentration at 72 hours. Started Oct 2025; status: completed.
02
Drugs
atorvastatin + ezetimibe + bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07235189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235189.